Sonnet BioTherapeutics ($SONN) is making waves with its high-stakes evolution — expanding its immunotherapy pipeline while diving headfirst into crypto with a jaw-dropping $888 million merger involving HYPE token holdings. 🎯 In this video, we reveal a timely trading plan based on Sonnet’s massive clinical momentum (SON-1010 + atezolizumab in ovarian cancer) and its bold diversification into blockchain treasury management. 🚀

Founded as a clinical-stage biotech, Sonnet focuses on oncology immunotherapies built on a Fully Human Albumin Binding (FHAB) platform to enhance cytokine delivery. But now, it's grabbing headlines for fusing that mission with digital assets — is it genius or desperation?

We analyze the latest earnings shocker 📉, the analyst price target of $20 (+657% upside), the insane revenue growth forecast, and what the market signals (RSI, support zones) mean for swing traders and long-term speculators alike. 🧠 Whether you’re bullish on the trial data or skeptical of the crypto gamble, this video gives you the trade setup you need.

📌 Watch till the end to catch our risk-managed trading strategy tailored for this volatile market setup!

#SONN #biotechstocks #cryptostocks #tradingplan #immunotherapy #stockanalysis #technicalanalysis #cryptomerger #ovariancancer #earlystagestocks #nasdaq

Sonnet BioTherapeutics: $888M Deal + Trial Expansion!🔥📈 Trading Plan? #SONNAsk ChatGPT